Abstract: This invention relates to small and intermediate conductance, calcium-activated potassium channel proteins. More specifically, the invention relates to compositions and methods for making and detecting calcium-activated potassium channel proteins and the nucleic acids encoding calcium-activated potassium channel proteins. The invention also provides methods and compositions for assaying compounds which increase or decrease potassium ion flux through a calcium-activated potassium channel.
Type:
Grant
Filed:
April 2, 2002
Date of Patent:
December 7, 2004
Assignees:
Oregon Health Sciences University, Icagen, Inc.
Inventors:
John P. Adelman, James Maylie, Chris T. Bond, Christopher P. Silvia
Abstract: This invention relates to small and intermediate conductance, calcium-activated potassium channel proteins. More specifically, the invention relates to compositions and methods for making and detecting calcium-activated potassium channel proteins and the nucleic acids encoding calcium-activated potassium channel proteins. The invention also provides methods and compositions for assaying compounds which increase or decrease potassium ion flux through a calcium-activated potassium channel.
Type:
Grant
Filed:
April 3, 2002
Date of Patent:
December 7, 2004
Assignees:
Oregon Health Sciences University, Icagen, Inc.
Inventors:
John P. Adelman, James Maylie, Chris T. Bond, Christopher P. Silvia
Abstract: This invention relates to small and intermediate conductance, calcium-activated potassium channel proteins. More specifically, the invention relates to compositions and methods for making and detecting calcium-activated potassium channel proteins and the nucleic acids encoding calcium-activated potassium channel proteins. The invention also provides methods and compositions for assaying compounds which increase or decrease potassium ion flux through a calcium-activated potassium channel.
Type:
Grant
Filed:
April 3, 2002
Date of Patent:
December 7, 2004
Assignees:
Oregon Health Sciences University, Icagen, Inc.
Inventors:
John P. Adelman, James Maylie, Chris T. Bond, Christopher P. Silvia
Abstract: Cloning, expression, viral and delivery vectors and hosts which contain nucleic acid coding for at least one peripheral nervous system specific (PNS) sodium channel peptide (SCP), isolated PNS SCP, and compounds and compositions and methods, are provided, for isolating, crystallizing, x-ray analysing molecular modeling, rational drug designing, selecting, making and using therapeutic or diagnostic agents or ligands having at least one peripheral nervous system specific (PNS) sodium channel (SC) modulating activity.
Type:
Application
Filed:
January 29, 2004
Publication date:
November 18, 2004
Applicants:
The Research Foundation of State University of New York, The SUNY at Stony Brook, ICAgen, Inc. (Allelix cases)
Abstract: The invention provides isolated nucleic acid and amino acid sequences of Slo3, a pH sensitive potassium channel expressed in sperm; antibodies to Slo3; methods of screening for Slo3 inhibitors; and methods of screening for Slo3 homologs.
Type:
Grant
Filed:
October 21, 1998
Date of Patent:
November 9, 2004
Assignees:
Icagen, Incorporated, The Washington University
Inventors:
Lawrence Salkoff, Matthew Schreiber, Chris Silvia
Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazolinone, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety and motor neuron diseases) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions.
Type:
Application
Filed:
December 23, 2003
Publication date:
October 7, 2004
Applicant:
ICAgen, Inc.
Inventors:
Grant A. McNaughton-Smith, James B. Thomas, George S. Amato
Abstract: This invention relates to small and intermediate conductance, calcium-activated potassium channel proteins. More specifically, the invention relates to compositions and methods for making and detecting calcium-activated potassium channel proteins and the nucleic acids encoding calcium-activated potassium channel proteins. The invention also provides methods and compositions for assaying compounds which increase or decrease potassium ion flux through a calcium-activated potassium channel.
Type:
Grant
Filed:
May 24, 1999
Date of Patent:
September 28, 2004
Assignees:
ICAgen, Incorporated, Oregon Health Sciences University
Inventors:
John P. Adelman, James Maylie, Chris T. Bond, Christopher P. Silvia
Abstract: A method for screening compounds for biological activity is disclosed. In one embodiment, a test library of compounds is selected. Then, a first analytical model is formed using a first recursive partitioning process using a digital computer. The first recursive partitioning process is performed on at least some of the compounds in the test library of compounds. Subsequent analytical models are formed using subsequent recursive partitioning processes using the digital computer. The subsequent recursive partitioning processes are performed on at least some of the compounds in the test library of compounds. Then, a consensus compound set is determined using the first analytical model and one or more of the subsequent analytical models.
Abstract: Benzanilides are provided which are voltage-dependent potassium channel openers. Methods of using the benzanilides of the invention are also provided.
Type:
Application
Filed:
February 2, 2004
Publication date:
August 12, 2004
Applicant:
ICAgen, Inc.
Inventors:
Grant A. McNaughton-Smith, Michael F. Gross, Alan D. Wickenden
Abstract: The invention provides isolated nucleic acid and amino acid sequences of Slo potassium family members such as, antibodies to Kv10 subfamily members such as Kv10.1, methods of detecting Kv10, subfamily members such as Kv10.1, methods of screening for potassium channel activators and inhibitors using biologically active Kv10 subfamily members such as Kv10.1, and kits for screening for activators and inhibitors of voltage-gated potassium channels comprising Kv10 subfamily members such as Kv10.1.
Abstract: The invention provides isolated nucleic acid and amino acid sequences of Kv6.2, antibodies to Kv6.2, methods of detecting Kv6.2, methods of screening for voltage-gated potassium channel activators and inhibitors using biologically active Kv6.2, and kits for screening for activators and inhibitors of voltage gated potassium channels comprising Kv6.2.
Abstract: The invention provides isolated nucleic acid and amino acid sequences of Eag2, antibodies to Eag2, methods of detecting Eag2, and methods of screening for modulators of Eag2 potassium channels using biologically active Eag2. The invention further provides, in a computer system, a method of screening for mutations of human Eag2 genes as well as a method for identifying a three-dimensional structure of Eag2 polypeptide monomers.
Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides sulfonamides, and compositions and methods utilizing sulfonamides that are useful in the treatment of diseases by blocking potassium channels associated with the onset or recurrence of the indicated conditions. Exemplary diseases treatable with the compounds, compositions and methods of the invention include sickle cell disease and glaucoma.
Type:
Application
Filed:
August 14, 2003
Publication date:
June 3, 2004
Applicant:
Icagen, Inc.
Inventors:
Grant A. McNaughton-Smith, Aimee D. Reed, Robert N. Atkinson
Abstract: Benzanilides are provided which are voltage-dependent potassium channel openers. Methods of using the benzanilides of the invention are also provided.
Type:
Grant
Filed:
November 1, 2001
Date of Patent:
May 18, 2004
Assignee:
ICAgen, Inc.
Inventors:
Grant A. McNaughton-Smith, Michael F. Gross, Alan D. Wickenden
Abstract: The invention provides isolated nucleic acid and amino acid sequences of Slo potassium family members such as, antibodies to Kv10 subfamily members such as Kv10.1, methods of detecting Kv10, subfamily members such as Kv10.1, methods of screening for potassium channel activators and inhibitors using biologically active Kv10 subfamily members such as Kv10.1, and kits for screening for activators and inhibitors of voltage-gated potassium channels comprising Kv10 subfamily members such as Kv10.1.
Abstract: This invention relates to small and intermediate conductance, calcium-activated potassium channel proteins. More specifically, the invention relates to compositions and methods for making and detecting calcium-activated potassium channel proteins and the nucleic acids encoding calcium-activated potassium channel proteins. The invention also provides methods and compositions for assaying compounds which increase or decrease potassium ion flux through a calcium-activated potassium channel.
Type:
Grant
Filed:
August 3, 2001
Date of Patent:
February 17, 2004
Assignees:
ICAgen, Incorporated, Oregon Health Sciences University
Inventors:
John P. Adelman, James Maylie, Chris T. Bond, Christopher P. Silvia
Abstract: This invention relates to the use of compounds able to decrease potassium ion flow through intermediate conductance calcium activated potassium channels for treatment of diseases related to increased intraocular pressure modulated by intermediate conductance calcium activated potassium channels.
Type:
Application
Filed:
February 28, 2003
Publication date:
February 12, 2004
Applicant:
Icagen, Inc.
Inventors:
Gregory C. Rigdon, Jonathan W. Stocker, Grant A. McNaughton-Smith
Abstract: The present invention provides a genus of bis-benzimidazole compounds, methods and pharmaceutical compositions that are useful as modulators of potassium ion channels. The compounds of the invention are of use in both therapeutic and diagnostic methods.
Type:
Application
Filed:
May 13, 2003
Publication date:
February 12, 2004
Applicant:
ICAgen, Inc.
Inventors:
Xiaodong Wang, Alan B. Fulp, Albert M. van Rhee, Kerry L. Spear
Abstract: The invention provides isolated nucleic acid and amino acid sequences of Kv6.2, antibodies to Kv6.2, methods of detecting Kv6.2, methods of screening for voltage-gated potassium channel activators and inhibitors using biologically active Kv6.2, and kits for screening for activators and inhibitors of voltage gated potassium channels comprising Kv6.2.
Abstract: Compounds which are useful as potassium channel inhibitors and which because of their slow off-rates are especially useful for the treatment of cardiac arrhythmias are described.
Type:
Application
Filed:
March 19, 2003
Publication date:
December 25, 2003
Applicant:
Icagen, Inc.
Inventors:
Aimee Dolores Reed, Michael Francis Gross, Serge Beaudoin